<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107938</url>
  </required_header>
  <id_info>
    <org_study_id>Livzon-IY-81149R-09</org_study_id>
    <secondary_id>SFDA2004L00137</secondary_id>
    <nct_id>NCT01107938</nct_id>
  </id_info>
  <brief_title>Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients</brief_title>
  <official_title>Efficacy and Safety of Ilaprazole for GERD: A Randomized,Double-Blind, Esomeprazole-Controlled,Phase2,Multicenter Trial in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Livzon Pharmaceutical Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Livzon Pharmaceutical Group Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to
      that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of
      GERD.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients with healed esophagitis at week 8</measure>
    <time_frame>week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of patients healed at week 4</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resolution of clinical symptoms</measure>
    <time_frame>week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>10 mg ilaprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg ilaprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg esomeprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg ilaprazole</intervention_name>
    <description>Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks</description>
    <arm_group_label>10 mg ilaprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15 mg ilaprazole</intervention_name>
    <description>Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks</description>
    <arm_group_label>15 mg ilaprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>40 mg esomeprazole</intervention_name>
    <description>One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks</description>
    <arm_group_label>40 mg esomeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consenting patients will be eligible for enrollment if they:

               -  are 18-70 years of age,

               -  have at least one of the two symptoms, heartburn and reflux,

               -  have photographically documented erosive esophagitis confirmed by
                  esophagogastroduodenoscopy(EGD), and graded according to the Los Angeles (LA)
                  Classification (A-D), within 5 days before randomization to treatment. Female
                  patients are required to be nonpregnant, nonlactating, postmenopausal, surgically
                  sterilized, or using a medically acceptable form of birth control, as determined
                  by the investigator. Women of child- bearing potential will receive a pregnancy
                  test.

        Exclusion Criteria:

          -  Patients will be ineligible if they:

               -  have cancerous or peptic ulcers, Zollinger-Ellison syndrome, varices of esophagus
                  or fundus of stomach

               -  have a known history of gastric acid suppression operation, esophageal operation
                  or peptic operation other than simple closure of perforation,

               -  have severe complications, severe other diseases of digestive tract such as
                  Crohn's disease and ulcerative colitis, and severe other systemic diseases,

               -  have taken proton pump inhibitors within the 5 days or for more than three
                  consecutive days within the two weeks immediately preceding start of study drug,

               -  participated in a clinical trial with an investigational drug or device within
                  the past three months,

               -  have hypersensitivity or idiosyncratic reaction to ilaprazole, esomeprazole or
                  any other benzimidazole,

               -  have alcoholic intemperance, drug addiction or any other improper habits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanren Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Liya Zhou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haitang Hu, MD</last_name>
    <phone>+86 13892890474</phone>
    <email>wl1020_2000@126.com</email>
  </overall_contact>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <last_update_submitted>April 20, 2010</last_update_submitted>
  <last_update_submitted_qc>April 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2010</last_update_posted>
  <responsible_party>
    <name_title>Haitang Hu</name_title>
    <organization>Livzon Pharmaceutical Group Inc.</organization>
  </responsible_party>
  <keyword>GERD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

